International Journal of
Reproductive Biomedicine
Sat, Nov 23, 2024
[Archive]
Volume 19, Issue 2 (February 2021)
IJRM 2021, 19(2): 157-166 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Khodadadian A, Varghaiyan Y, Babakhanzadeh E, Alipourfard I, Haghi-Daredeh S, Ghobadi A, et al . Fertility preservation in women with ovarian cancer: Finding new pathways: A case-control study. IJRM 2021; 19 (2) :157-166
URL: http://ijrm.ir/article-1-1575-en.html
URL: http://ijrm.ir/article-1-1575-en.html
Ali Khodadadian * 
1, Yasser Varghaiyan2 , Emad Babakhanzadeh3 , Iraj Alipourfard4 , Saeed Haghi-Daredeh5 , Amin Ghobadi6 , Mohsen Hemmati-Dinarvand7 , Mehrdad Talebi3 , Nasrin Ghasemi8
1, Yasser Varghaiyan2 , Emad Babakhanzadeh3 , Iraj Alipourfard4 , Saeed Haghi-Daredeh5 , Amin Ghobadi6 , Mohsen Hemmati-Dinarvand7 , Mehrdad Talebi3 , Nasrin Ghasemi8
1- Department of Medical Genetics, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. , Ali.khodadadian@yahoo.com
2- Department of Immunology, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
3- Department of Medical Genetics, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
4- Center of Pharmaceutical Sciences, Faculty of Life Sciences, University of Vienna, Vienna, Austria. School of Pharmacy, Faculty of Sciences, University of Rome Tor Vergata, Rome, Italy.
5- Department of Medical Nanotechnology, School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran.
6- Department of Clinical Biochemistry and Laboratory Medicine, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
7- Department of Clinical Biochemistry and Laboratory Medicine, Faculty of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
8- Abortion Research Centre, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
2- Department of Immunology, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
3- Department of Medical Genetics, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
4- Center of Pharmaceutical Sciences, Faculty of Life Sciences, University of Vienna, Vienna, Austria. School of Pharmacy, Faculty of Sciences, University of Rome Tor Vergata, Rome, Italy.
5- Department of Medical Nanotechnology, School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran.
6- Department of Clinical Biochemistry and Laboratory Medicine, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
7- Department of Clinical Biochemistry and Laboratory Medicine, Faculty of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
8- Abortion Research Centre, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Abstract: (1920 Views)
Background: Surgery and chemotherapy are the two most common treatments for cancers, including ovarian cancer. Although most ovarian cancers occur over the age of 45 yr, it may involve younger women and affect their reproductive ability.
Objective: To assess the expression of Leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5), Forkhead Box O1 (FOXO1), and miR-340 genes in the ovarian cancer tissues as well as ovarian cancer cell lines.
Materials and Methods: In this case-control study, 30 ovarian cancer samples (with the average age of 37 ± 2.5 years) coupled with their non-tumor marginal tissue (as a control) were collected. Proliferated cell lines were treated with several concentrations of cisplatin, and the half maximal inhibitory concentration (IC50) of cisplatin was quantified by MTT-assay. After RNA extraction, cDNA synthesis and qRT-PCR were done. Finally, the results were analyzed.
Results: While the expression levels of miR-340 and FOXO1 genes in tumor samples displayed a significant reduction (p ≤ 0.001), the LGR5 gene presented a significant increase in expression (p ≤ 0.0001). However, conversely, the expression levels of miR-340 and FOXO1 genes in cisplatin-sensitive cell lines, after 24, 48, and 72 hr of cisplatin treatment, indicated a significant increase (p ≤ 0.001) while the expression of LGR5 gene showed a significant decrease in the cisplatin-sensitive cell line (p < 0.05).
Conclusion: The LGR5, FOXO1, and miR-340 genes can be targeted for early diagnosis and more accurate treatment of ovarian cancer and may prevent some of the ovarian cancer complications such as infertility.
Objective: To assess the expression of Leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5), Forkhead Box O1 (FOXO1), and miR-340 genes in the ovarian cancer tissues as well as ovarian cancer cell lines.
Materials and Methods: In this case-control study, 30 ovarian cancer samples (with the average age of 37 ± 2.5 years) coupled with their non-tumor marginal tissue (as a control) were collected. Proliferated cell lines were treated with several concentrations of cisplatin, and the half maximal inhibitory concentration (IC50) of cisplatin was quantified by MTT-assay. After RNA extraction, cDNA synthesis and qRT-PCR were done. Finally, the results were analyzed.
Results: While the expression levels of miR-340 and FOXO1 genes in tumor samples displayed a significant reduction (p ≤ 0.001), the LGR5 gene presented a significant increase in expression (p ≤ 0.0001). However, conversely, the expression levels of miR-340 and FOXO1 genes in cisplatin-sensitive cell lines, after 24, 48, and 72 hr of cisplatin treatment, indicated a significant increase (p ≤ 0.001) while the expression of LGR5 gene showed a significant decrease in the cisplatin-sensitive cell line (p < 0.05).
Conclusion: The LGR5, FOXO1, and miR-340 genes can be targeted for early diagnosis and more accurate treatment of ovarian cancer and may prevent some of the ovarian cancer complications such as infertility.
Type of Study: Original Article |
Subject:
Reproductive Oncology
References
1. Wang Y, Sheng Q, Spillman MA, Behbakht K, Gu H. Gab2 regulates the migratory behaviors and E-cadherin expression via activation of the PI3K pathway in ovarian cancer cells. Oncogene 2012; 31: 2512-2520. [DOI:10.1038/onc.2011.435] [PMID] [PMCID]
2. Berry NB, Bapat SA. Ovarian cancer plasticity and epigenomics in the acquisition of a stem-like phenotype. J Ovarian Res 2008; 1: 8. [DOI:10.1186/1757-2215-1-8] [PMID] [PMCID]
3. Hancke K, Isachenko V, Isachenko E, Weiss JM. Prevention of ovarian damage and infertility in young female cancer patients awaiting chemotherapy--clinical approach and unsolved issues. Support Care Cancer 2011; 19: 1909-1919. [DOI:10.1007/s00520-011-1261-2] [PMID]
4. Gaffan J, Holden L, Newlands ES, Short D, Fuller S, Begent RH, et al. Infertility rates following POMB/ACE chemotherapy for male and female germ cell tumours - a retrospective long-term follow-up study. Br J Cancer 2003; 89: 1849-1854. [DOI:10.1038/sj.bjc.6601383] [PMID] [PMCID]
5. Kerr JB, Hutt KJ, Cook M, Speed TP, Strasser A, Findlay JK, et al. Cisplatin-induced primordial follicle oocyte killing and loss of fertility are not prevented by imatinib. Nat Med 2012; 18: 1170-1172. [DOI:10.1038/nm.2889] [PMID] [PMCID]
6. Hseu Y-C, Lin Y-C, Rajendran P, Thigarajan V, Mathew DC, Lin K-Y, et al. Antrodia salmonea suppresses invasion and metastasis in triple-negative breast cancer cells by reversing EMT through the NF-κB and Wnt/β-catenin signaling pathway. Food Chem Toxicol 2018; 124: 219-230. [DOI:10.1016/j.fct.2018.12.009] [PMID]
7. Kobayashi S, Yamada‐Okabe H, Suzuki M, Natori O, Kato A, Matsubara K, et al. LGR5‐positive colon cancer stem cells interconvert with drug‐resistant LGR5‐negative cells and are capable of tumor reconstitution. Stem Cells 2012; 30: 2631-2644. [DOI:10.1002/stem.1257] [PMID]
8. Wachtel M, Schafer BW. PAX3-FOXO1: Zooming in on an "undruggable" target. Semin Cancer Biol 2018; 50: 115-123. [DOI:10.1016/j.semcancer.2017.11.006] [PMID]
9. Zhao Y, Tindall DJ, Huang H. Modulation of androgen receptor by FOXA1 and FOXO1 factors in prostate cancer. Int J Biol Sci 2014; 10: 614-619. [DOI:10.7150/ijbs.8389] [PMID] [PMCID]
10. Choi Y, Park J, San Ko Y, Kim Y, Pyo J-S, Jang BG, et al. FOXO1 reduces tumorsphere formation capacity and has crosstalk with LGR5 signaling in gastric cancer cells. Biochem Biophys Res Commun 2017; 493: 1349-1355. [DOI:10.1016/j.bbrc.2017.09.163] [PMID]
11. Vallvé-Juanico J, Barón C, Suárez-Salvador E, Castellví J, Ballesteros A, Gil-Moreno A, et al. Lgr5 does not vary throughout the menstrual cycle in endometriotic human eutopic endometrium. Int J Mol Sci 2019; 20: 22. [DOI:10.3390/ijms20010022] [PMID] [PMCID]
12. Vallvé-Juanico J, Suárez-Salvador E, Castellví J, Ballesteros A, Taylor HS, Gil-Moreno A, et al. Aberrant expression of epithelial leucine-rich repeat containing G protein-coupled receptor 5-positive cells in the eutopic endometrium in endometriosis and implications in deep-infiltrating endometriosis. Fertil Steril 2017; 108: 858-867. [DOI:10.1016/j.fertnstert.2017.08.018] [PMID]
13. Vasquez YM, Wang X, Wetendorf M, Franco HL, Mo Q, Wang T, et al. FOXO1 regulates uterine epithelial integrity and progesterone receptor expression critical for embryo implantation. PLoS Genet 2018; 14: e1007787. [DOI:10.1371/journal.pgen.1007787] [PMID] [PMCID]
14. Ting AY, Zelinski MB. Characterization of FOXO1, 3 and 4 transcription factors in ovaries of fetal, prepubertal and adult rhesus macaques. Biol Reprod 2017; 96: 1052-1059. [DOI:10.1093/biolre/iox034] [PMID] [PMCID]
15. Karami N, Mirabutalebi SH, Montazeri F, Kalantar SM, Sheikhha MH, Eftekhar M. Aberrant expression of microRNAs 16 and 21 and gene targets in women with unexplained recurrent miscarriage: A case-control study. Int J Reprod BioMed 2018; 16: 617-622. [DOI:10.29252/ijrm.16.10.617] [PMID] [PMCID]
16. Khodadadian A, Hemmati-Dinarvand M, Kalantary-Charvadeh A, Ghobadi A, Mazaheri M. Candidate biomarkers for Parkinson's disease. Biomed Pharmacother 2018; 104: 699-704. [DOI:10.1016/j.biopha.2018.05.026] [PMID]
17. Mirabutalebi SH, Karami N, Montazeri F, Fesahat F, Sheikhha MH, Hajimaqsoodi E, et al. The relationship between the expression levels of miR-135a and HOXA10 gene in the eutopic and ectopic endometrium. Int J Reprod BioMed 2018; 16: 501-506. [DOI:10.29252/ijrm.16.8.501] [PMID] [PMCID]
18. Shi S, Chen X, Liu H, Yu K, Bao Y, Chai J, et al. LGR5 acts as a target of miR-340-5p in the suppression of cell progression and drug resistance in breast cancer via Wnt/beta-catenin pathway. Gene 2019; 683: 47-53. [DOI:10.1016/j.gene.2018.10.014] [PMID]
19. Park J, Choi Y, San Ko Y, Kim Y, Pyo J-S, Jang BG, et al. FOXO1 suppression is a determinant of acquired lapatinib-resistance in HER2-positive gastric cancer cells through MET upregulation. Cancer Res Treat 2018; 50: 239-254. [DOI:10.4143/crt.2016.580] [PMID] [PMCID]
20. Zhang L, Guo X, Zhang D, Fan Y, Qin L, Dong S, et al. Upregulated miR-132 in Lgr5(+) gastric cancer stem cell-like cells contributes to cisplatin-resistance via SIRT1/CREB/ABCG2 signaling pathway. Mol Carcinog 2017; 56: 2022-2034. [DOI:10.1002/mc.22656] [PMID]
21. Shi L, Chen ZG, Wu LL, Zheng JJ, Yang JR, Chen XF, et al. miR-340 reverses cisplatin resistance of hepatocellular carcinoma cell lines by targeting Nrf2-dependent antioxidant pathway. Asian Pac J Cancer Prev 2014; 15: 10439-10444. [DOI:10.7314/APJCP.2014.15.23.10439] [PMID]
22. Song L, Duan P, Gan Y, Li P, Zhao C, Xu J, et al. MicroRNA-340-5p modulates cisplatin resistance by targeting LPAATβ in osteosarcoma. Braz J Med Biol Res 2017; 50: e6359. [DOI:10.1590/1414-431x20176359] [PMID] [PMCID]
23. Gao Zh, Liu R, Ye N, Liu Ch, Li X, Guo X, et al. FOXO1 inhibits tumor cell migration via regulating cell surface morphology in non-small cell lung cancer cells. Cell Physiol Biochem 2018; 48: 138-148. [DOI:10.1159/000491670] [PMID]
24. Shi S, Chen X, Liu H, Yu K, Bao Y, Chai J, et al. LGR5 acts as a target of miR-340-5p in the suppression of cell progression and drug resistance in breast cancer via Wnt/β-catenin pathway. Gene 2019; 683: 47-53. [DOI:10.1016/j.gene.2018.10.014] [PMID]
25. Cao HZ, Liu XF, Yang WT, Chen Q, Zheng PS. LGR5 promotes cancer stem cell traits and chemoresistance in cervical cancer. Cell Death Dis 2017; 8: e3039. [DOI:10.1038/cddis.2017.393] [PMID] [PMCID]
26. Vasquez YM, Wang X, Wetendorf M, Franco HL, Mo Q, Wang T, et al. FOXO1 regulates uterine epithelial integrity and progesterone receptor expression critical for embryo implantation. PLos Genet 2018; 14: e1007787. [DOI:10.1371/journal.pgen.1007787] [PMID] [PMCID]
27. Park J, Choi Y, San Ko Y, Kim Y, Pyo J-S, Jang BG, et al. FOXO1 suppression is a determinant of acquired lapatinib-resistance in HER2-positive gastric cancer cells through MET upregulation. Cancer Res Treat 2018; 50: 239-254. [DOI:10.4143/crt.2016.580] [PMID] [PMCID]
28. Rezaei Z, Sebzari A, Kordi-Tamandani DM, Dastjerdi K. Involvement of the dysregulation of Mir-23b-3p, Mir-195-5p, Mir-656-5p, and Mir-340-5p in trastuzumab resistance of HER2-positive breast cancer cells and system biology approach to predict their targets involved in resistance. DNA Cell Biol 2019; 38: 184-192. [DOI:10.1089/dna.2018.4427] [PMID]
29. Schuldes H, Bade S, Knobloch J, Jonas D. Loss of in vitro cytotoxicity of cisplatin after storage as stock solution in cell culture medium at various temperatures. Cancer 1997; 79: 1723-1728.
https://doi.org/10.1002/(SICI)1097-0142(19970501)79:9<1723::AID-CNCR13>3.0.CO;2-# [DOI:10.1002/(SICI)1097-0142(19970501)79:93.0.CO;2-#]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
